Sanofi SA / Tidal Therapeutics, Inc.

Immuno-oncology and inflammatory diseases (in vivo mRNA immune cell reprogramming)

1.9M US cases/yr · $185.0B Global oncology drug spending 2021 (USD MM, IQVIA) · 7 FDA-approved CAR-T therapies through 2024 (count)

Disease Overview

In vivo mRNA-based reprogramming of immune cells targets the broader immuno-oncology and immune-mediated disease landscape, where unmet need remains substantial despite the success of checkpoint inhibitors and ex vivo CAR-T therapies. The American Cancer Society projected approximately 1.9 million new US cancer diagnoses in 2021, of which roughly 600,000 patients have advanced or metastatic solid tumors that are largely unresponsive to current immunotherapies — only 15-25% of patients across most solid tumor indications achieve durable benefit from anti-PD-1/PD-L1 monotherapy. Ex vivo CAR-T (Kymriah, Yescarta, Tecartus, Breyanzi, Abecma) has transformed B-cell hematologic malignancies but remains limited by manufacturing complexity, $400K-475K list prices, vein-to-vein time, lymphodepleting conditioning, cytokine release syndrome risk, and inadequate scale for prevalent solid tumor populations. In parallel, immune-mediated inflammatory diseases (rheumatoid arthritis, IBD, psoriasis, MS, lupus) collectively affect more than 25 million Americans and drove >$70B in global biologic sales in 2021. Tidal's lipid nanoparticle (LNP) mRNA platform aimed to bypass autologous cell engineering by delivering mRNA encoding chimeric antigen receptors or transcription factors directly to immune cells in patients, potentially expanding cell therapy reach to broader oncology populations and chronic immune indications.

Competitive Landscape

Tidal's in vivo mRNA immune-cell reprogramming platform sat in a crowded but early-stage MOA landscape at deal date (April 2021). Direct comparators developing in vivo CAR delivery via LNP-mRNA included Capstan Therapeutics (founded 2022, in vivo CAR-T via LNP-mRNA, Pfizer-backed), Umoja Biopharma (VivoVec lentiviral in vivo CAR-T), Orna Therapeutics (circular RNA CAR delivery, Merck partnership), Cartesian Therapeutics (Descartes-08 mRNA CAR-T for autoimmune), and Moderna (mRNA cancer vaccines including mRNA-4157/V940 with Merck). Adjacent allogeneic ex vivo platforms include Allogene (ALLO-501/A AlloCAR-T), Caribou Biosciences (CB-010), Precision BioSciences (PBCAR0191), Fate Therapeutics (FT516/FT596 iPSC-NK) and Atara Biotherapeutics (allogeneic EBV-T). Big pharma mRNA stakes had accelerated post-COVID: BioNTech (BNT211 CLDN6 CAR-T plus mRNA cancer vaccine pipeline), Moderna-Merck mRNA-4157, AstraZeneca-Moderna AZD8601 cardiac mRNA. Sanofi's $470M Tidal acquisition complemented its August 2020 Translate Bio mRNA partnership ($425M) and the subsequent $3.2B Translate Bio acquisition (August 2021), cementing Sanofi's mRNA platform stack across vaccines, immuno-oncology, and inflammatory diseases.